Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep805 | Pituitary and Neuroendocrinology | ECE2023

Secondary amenorrhea revealing pituitary sarcoidosis: a case report and review of the literature

Fatima Ezzahra Mennani , Camara Mballou , Rafi Sana , Elmghari Ghizlane , EL Ansari Nawal

Introduction: Hypothalamic-pituitary involvement during sarcoidosis is rare, less than 1%. Granulomatous infiltration can lead to anteropituitary insufficiency, disconnection hyperprolactinemia and diabetes insipidus. We report a case of hypothalamic-pituitary sarcoidosis with review of the literature.Observation: Patient aged 39 years, she complains of chronic headaches for 10 months without decrease in visual acuity, secondary amenorrhea for 6 months. ...

ea0090ep950 | Reproductive and Developmental Endocrinology | ECE2023

Curschmann Steinert disease and related endocrine disorders

Fatima Ezzahra Mennani , Douali Ouidad , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Steinert’s myotonic dystrophy (SMD) is a neuromuscular disorder with a multisystem distribution. It is a genetic disease with autosomal dominant transmission. It may be associated with various endocrine disorders.Observation: We report the case of a 47-year-old patient followed for DM since the age of 18, diabetic under insulin therapy for 20 years, hypertensive for 1 year under losartan 50 mg/d who was referred to us for evaluation of...

ea0099ep515 | Calcium and Bone | ECE2024

Evaluation of bone status in obese women: about 48 cases

Haouach Salsabil , Fatima Ezzahra Mennani , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Obesity has become a major health problem and a global epidemic, with a worldwide prevalence that has doubled over the last three decades. According to the WHO, obesity is defined as a body mass index of 30 kg/m2 or more The relationship between obesity and bone capital has been proven. A few years ago, it was thought that obesity had a protective effect on bone, a belief that influenced clinical practice. However, various pathogenic mechanisms, notably vitaminD ...

ea0099ep101 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Side effects of mesenchymal stem cell transplantation in type 1 diabetics department of endocrinology, diabetology, metabolic

Fatima Ezzahra Mennani , Rafi Sana , EL Mghari Ghizlane , EL Ansari Nawal

Introduction: According to numerous studies, mesenchymal stem cell therapy is one of the best therapeutic approaches for the treatment of type 1 diabetes. The aim of our study is to provide an update on the contribution of mesenchymal stem cells to glycaemic control and the screening of short-and long-term side effects.Results: We included 5 patients who met our inclusion criteria. The mean age was 21.2 years, with a sex ratio of 0.6. The average duratio...

ea0099ep1022 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Environmental endocrine disruptors and obesity: what is the causal link?

fatima ezzahra Mennani , Ouakrim Hind , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Endocrine disruptors are natural or chemical molecules capable of interfering with the endocrine system, as well as disrupting the signaling pathways of carbohydrate and lipid metabolism.Materials and methods: This is a retrospective study of 85 patients with a BMI greater than 30 kg/m2 followed in the endocrinology department of CHU Mohamed VI; we studied exposure to endocrine disruptors.Results: 85 patien...

ea0099ep1006 | Endocrine-Related Cancer | ECE2024

Successful control of hypoglycemia with Lanreotide in a patient with nesidioblastosis

Fatima Ezzahra Mennani , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Nesidioblastosis is a rare disease caused by hyperplasia of the pancreatic islets, resulting in hypoglycaemia due to increased insulin production. It is the main cause of hyperinsulin hypoglycaemia in children, although it accounts for only 0.5 to 5% of cases in adults. We report here the case of a patient with neidioblastosis successfully treated with lanreotide 120 mg LP, after persistent hypoglycaemia post-surgery.Clinical case: A 62-yea...